Adaptive Biotechnologies announced that clonoSEQ is now available to health care providers as a fully integrated test in Aura, Epic’s specialty diagnostics suite. This integration will allow providers to order and review clonoSEQ minimal residual disease testing results in Epic as they would for any test performed directly at the site of care. Under the partnership established in September 2022, clonoSEQ is available to healthcare providers through Aura, Epic’s specialty diagnostics suite.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ADPT:
- Adaptive Announces Launch of Epic Integration for clonoSEQ®
- Adaptive Biotechnologies to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
- Cathie Wood’s ARK Investment bought 176.1K shares of Adaptive Biotechnologies
- Cathie Wood’s ARK Investment bought 170K shares of Adaptive Biotechnologies
- Adaptive Biotechnologies price target lowered to $14 from $15 at Piper Sandler
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue